Evidence map›Paper›PMID 32019170›Full record

SynthesisInternational journal of molecular sciences2020

Salivary MicroRNA for Diagnosis of Cancer and Systemic Diseases: A Systematic Review.

Giacomo Setti, Margherita E Pezzi, Maria Vittoria Viani, Thelma A Pertinhez, Diana Cassi, Cristina Magnoni, Pierantonio Bellini, Antonino Musolino, Paolo Vescovi, Marco Meleti

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Dysregulation ofCurrent Alzheimer research · 2024
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Giacomo SettiMolecular Medicine Ph.D. School, Department of Medicine and Surgery, University of Parma, 43125 Parma, Italy.
Margherita E PezziCentro Universitario di Odontoiatria-University of Parma, Via Gramsci 14, Parma, 43126, Italy.
Maria Vittoria VianiCentro Universitario di Odontoiatria-University of Parma, Via Gramsci 14, Parma, 43126, Italy.
Thelma A PertinhezDepartment of Medicine and Surgery-Via Volturno 39, 43125 Parma, Italy.
Diana CassiCentro Universitario di Odontoiatria-University of Parma, Via Gramsci 14, Parma, 43126, Italy.
Cristina MagnoniDermatology-Department of Surgical, Medical, Dental and Morphological Science with interest in Transplant Oncological and Regenerative Medicine-University of Modena and Reggio Emilia, Largo del Pozzo 71, 41125 Modena, Italy.
Pierantonio BelliniDentistry and Oral and Maxillofacial Surgery-Department of Surgical, Medical, Dental and Morphological Science with interest in Transplant Oncological and Regenerative Medicine-University of Modena and Reggio Emilia, Largo del Pozzo 71, 41125 Modena, Italy.
Antonino MusolinoMedical Oncology and Breast Unit, University Hospital of Parma - Via Gramsci 14, 43125 Parma, Italy.
Paolo VescoviCentro Universitario di Odontoiatria-University of Parma, Via Gramsci 14, Parma, 43126, Italy.
Marco MeletiCentro Universitario di Odontoiatria-University of Parma, Via Gramsci 14, Parma, 43126, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

methodsThe application of inclusion and exclusion criteria led to the selection of 11 papers. Critical appraisals and quality assessments of the selected studies were performed through the National Institute of Health "Study Quality Assessment Tool" and the classification of the Oxford Center for Evidence-Based Medicine.

resultsSeven studies reported statistically significant correlations between one or more salivary miRNAs and the investigated disease. The critical analysis allowed us to classify only two studies (18.2%) as having "good" quality, the rest being scored as "intermediate" (8; 73%) and "poor" (1; 9%). Evidence exists that salivary miR-940 and miR-3679-5p are reliable markers for pancreatic cancer and that miR140-5p and miR301a are promising molecules for the salivary diagnosis of gastric cancer.

conclusionsFurther studies, possibly avoiding the risk of bias highlighted here, are necessary to consolidate these findings and to identify new reliable salivary biomarkers.

Indexed as

Autoimmune DiseasesBiomarkersHumansInflammationMicroRNAsNeoplasmsSalivaBiomarkersMicroRNAsbiomarkerscancerdiagnosismiRNAsaliva

Identifiers

PMID32019170
PMCPMC7037322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.